Literature DB >> 19723881

Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.

Matthew A Bill1, Courtney Bakan, Don M Benson, James Fuchs, Gregory Young, Gregory B Lesinski.   

Abstract

Curcumin has potential as a chemopreventative and chemotherapeutic agent, but its interactions with clinically relevant cytokines are poorly characterized. Because cytokine immunotherapy is a mainstay of treatment for malignant melanoma, we hypothesized that curcumin could modulate the cellular responsiveness to interferons and interleukins. As a single agent, curcumin induced a dose-dependent increase in apoptosis of human melanoma cell lines, which was most prominent at doses >10 micromol/L. Immunoblot analysis confirmed that curcumin induced apoptosis and revealed caspase-3 processing, poly ADP ribose polymerase cleavage, reduced Bcl-2, and decreased basal phosphorylated signal transducers and activators of transcription 3 (STAT3). Despite its proapoptotic effects, curcumin pretreatment of human melanoma cell lines inhibited the phosphorylation of STAT1 protein and downstream gene transcription following IFN-alpha and IFN-gamma as determined by immunoblot analysis and real time PCR, respectively. Pretreatment of peripheral blood mononuclear cells from healthy donors with curcumin also inhibited the ability of IFN-alpha, IFN-gamma, and interleukin-2 to phosphorylate STAT proteins critical for their antitumor activity (STAT1 and STAT5, respectively) and their respective downstream gene expression as measured by real time PCR. Finally, stimulation of natural killer (NK) cells with curcumin reduced the level of interleukin-12-induced IFN-gamma secretion, and production of granzyme b or IFN-gamma upon coculture with A375 melanoma cells or NK-sensitive K562 cells as targets. These data show that although curcumin can induce apoptosis of melanoma cells, it can also adversely affect the responsiveness of immune effector cells to clinically relevant cytokines that possess antitumor properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723881      PMCID: PMC2748163          DOI: 10.1158/1535-7163.MCT-09-0377

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  69 in total

1.  Cutting edge: Enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity.

Authors:  Jason Waithman; Thomas Gebhardt; Gayle M Davey; William R Heath; Francis R Carbone
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  Curcuma longa L. constituents inhibit sortase A and Staphylococcus aureus cell adhesion to fibronectin.

Authors:  Byeoung-Soo Park; Jae-Gyu Kim; Mi-Ran Kim; Sung-Eun Lee; Gary R Takeoka; Ki-Bong Oh; Jeong-Han Kim
Journal:  J Agric Food Chem       Date:  2005-11-16       Impact factor: 5.279

6.  Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Authors:  Kimberly A Varker; Sri Vidya Kondadasula; Michael R Go; Gregory B Lesinski; Rupa Ghosh-Berkebile; Amy Lehman; J Paul Monk; Thomas Olencki; Kari Kendra; William E Carson
Journal:  Clin Cancer Res       Date:  2006-10-01       Impact factor: 12.531

7.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

Review 8.  Curcumin as "Curecumin": from kitchen to clinic.

Authors:  Ajay Goel; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

9.  IL-2 family of cytokines in T regulatory cell development and homeostasis.

Authors:  Thomas R Malek; Aixin Yu; Linjian Zhu; Takaji Matsutani; Dennis Adeegbe; Allison L Bayer
Journal:  J Clin Immunol       Date:  2008-08-26       Impact factor: 8.317

10.  Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay.

Authors:  Kimberly A Shafer-Weaver; Thomas Sayers; Douglas B Kuhns; Susan L Strobl; Mark W Burkett; Michael Baseler; Anatoli Malyguine
Journal:  J Transl Med       Date:  2004-09-20       Impact factor: 5.531

View more
  26 in total

1.  1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation.

Authors:  Teng Yu; Jinchao Li; Ying Qiu; Hui Sun
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2.

Authors:  Tianchi Cai; Yingmin Kuang; Chunhua Zhang; Zheng Zhang; Long Chen; Bo Li; Yuqian Li; Yanling Wang; Huixin Yang; Qiaoqiao Han; Yuechun Zhu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 3.  Cancer and diet: How are they related?

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Afsaneh Lavasanifar; Bharat B Aggarwal
Journal:  Free Radic Res       Date:  2011-06-09

Review 4.  Botanicals for the prevention and treatment of cutaneous melanoma.

Authors:  Deeba N Syed; Hasan Mukhtar
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-12       Impact factor: 4.693

Review 5.  Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

Authors:  Leah Ray Strickland; Harish Chandra Pal; Craig A Elmets; Farrukh Afaq
Journal:  Cancer Lett       Date:  2015-01-15       Impact factor: 8.679

6.  Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.

Authors:  Karuppaiyah Selvendiran; Shabnam Ahmed; Alex Dayton; M Lakshmi Kuppusamy; Mia Tazi; Anna Bratasz; Liyue Tong; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Free Radic Biol Med       Date:  2010-02-12       Impact factor: 7.376

Review 7.  Interface of signal transduction inhibition and immunotherapy in melanoma.

Authors:  Amber L Shada; Kerrington R Molhoek; Craig L Slingluff
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

8.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Authors:  Matthew A Bill; James R Fuchs; Chenglong Li; Jennifer Yui; Courtney Bakan; Don M Benson; Eric B Schwartz; Dalia Abdelhamid; Jiayuh Lin; Dale G Hoyt; Stacey L Fossey; Gregory S Young; William E Carson; Pui-Kai Li; Gregory B Lesinski
Journal:  Mol Cancer       Date:  2010-06-25       Impact factor: 27.401

9.  Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Vanessa Soto-Cerrato; Margarita Espona-Fiedler; Ricardo Pérez-Tomás; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2013-01-23

10.  Pyridine analogues of curcumin exhibit high activity for inhibiting CWR-22Rv1 human prostate cancer cell growth and androgen receptor activation.

Authors:  Dai-Ying Zhou; Su-Qing Zhao; Zhi-Yun DU; X I Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.